摘要
目的 探讨术后辅助化疗治疗晚期卵巢癌患者的临床疗效。方法 根据治疗方式的不同将116例晚期卵巢癌患者分为对照组(n=61,仅接受手术治疗)和联合化疗组(n=55,手术治疗后接受辅助化疗)。比较两组患者的临床疗效及复发、转移、生存情况。结果 联合化疗组患者的疾病控制率为96.36%,明显高于对照组患者的80.33%,差异有统计学意义(P﹤0.01)。联合化疗组患者的3年复发率和转移率均低于对照组,3年生存率高于对照组,差异均有统计学意义(P﹤0.05)。结论 术后化疗能够提高晚期卵巢癌患者的临床疗效,降低复发率和转移率,提高生存率。
Objective To investigate the clinical efficacy of postoperative adjuvant chemotherapy in patients with ad-vanced ovarian cancer.MethodA total of 116 patients with advanced ovarian cancer were divided into the control group(n=61,received surgery only)and the combined chemotherapy group(n=55,received surgery+adjuvant chemotherapy)according to different treatment methods.The clinical efficacy,recurrence,metastasis and survival of the two groups were compared.Result The disease control rate of the combined chemotherapy group was 96.36%,significantly higher than 80.33%of the control group,and the difference was statistically significant(P<0.01).The 3-year recurrence rate and me-tastasis rate in the combined chemotherapy group were lower than those in the control group,the 3-year survival rate was higher than that in the control group,and the differences were statistically significant(P<0.05).Conclusion Postopera-tive chemotherapy can improve the clinical efficacy of patients with advanced ovarian cancer,reduce recurrence rate and metastasis rate,and improve survival rate.
作者
方丽萍
李妮
貟海娟
高小翠
FANG Liping;LI Ni;YUN Haijuan;GAO Xiaocui(Department of Gynecology,Xi'an Gaoxin Hospital,Xi'an 710075,Shaanxi,China;Department of Obstetrics and Gynecology,General Global China Railway Xi'an Hospital,Xi'an 710054,Shaanxi,China)
出处
《癌症进展》
2023年第21期2423-2425,共3页
Oncology Progress
基金
吴阶平医学基金会临床科研专项资助基金(320.6750.18528)。
关键词
晚期卵巢癌
术后化疗
复发
转移
生存
advanced ovarian cancer
postoperative chemotherapy
recurrence
metastasis
survival
